JP2012509672A - 繊維状バクテリオファージを使用してパーキンソン病を処置するための方法 - Google Patents

繊維状バクテリオファージを使用してパーキンソン病を処置するための方法 Download PDF

Info

Publication number
JP2012509672A
JP2012509672A JP2011537703A JP2011537703A JP2012509672A JP 2012509672 A JP2012509672 A JP 2012509672A JP 2011537703 A JP2011537703 A JP 2011537703A JP 2011537703 A JP2011537703 A JP 2011537703A JP 2012509672 A JP2012509672 A JP 2012509672A
Authority
JP
Japan
Prior art keywords
bacteriophage
antibody
filamentous
synuclein
filamentous bacteriophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011537703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509672A5 (cg-RX-API-DMAC10.html
Inventor
ソロモン，ベカ
ダイマント，ハイム・エム
Original Assignee
ラモト アト テル−アヴィヴ ユニバーシティ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラモト アト テル−アヴィヴ ユニバーシティ リミテッド filed Critical ラモト アト テル−アヴィヴ ユニバーシティ リミテッド
Publication of JP2012509672A publication Critical patent/JP2012509672A/ja
Publication of JP2012509672A5 publication Critical patent/JP2012509672A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2011537703A 2008-11-24 2009-11-24 繊維状バクテリオファージを使用してパーキンソン病を処置するための方法 Pending JP2012509672A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11744608P 2008-11-24 2008-11-24
US61/117,446 2008-11-24
PCT/US2009/065659 WO2010060073A2 (en) 2008-11-24 2009-11-24 Method for treating parkinson's disease

Publications (2)

Publication Number Publication Date
JP2012509672A true JP2012509672A (ja) 2012-04-26
JP2012509672A5 JP2012509672A5 (cg-RX-API-DMAC10.html) 2013-01-24

Family

ID=41572327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537703A Pending JP2012509672A (ja) 2008-11-24 2009-11-24 繊維状バクテリオファージを使用してパーキンソン病を処置するための方法

Country Status (16)

Country Link
US (1) US20110286970A1 (cg-RX-API-DMAC10.html)
EP (2) EP2478911A1 (cg-RX-API-DMAC10.html)
JP (1) JP2012509672A (cg-RX-API-DMAC10.html)
KR (1) KR20110091778A (cg-RX-API-DMAC10.html)
CN (1) CN102223887B (cg-RX-API-DMAC10.html)
AU (1) AU2009316326A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0921557A2 (cg-RX-API-DMAC10.html)
CA (1) CA2744339A1 (cg-RX-API-DMAC10.html)
CO (1) CO6390112A2 (cg-RX-API-DMAC10.html)
IL (1) IL213120A0 (cg-RX-API-DMAC10.html)
MX (1) MX2011005430A (cg-RX-API-DMAC10.html)
NZ (1) NZ592928A (cg-RX-API-DMAC10.html)
RU (1) RU2011125971A (cg-RX-API-DMAC10.html)
SG (1) SG171791A1 (cg-RX-API-DMAC10.html)
WO (1) WO2010060073A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201104701B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2102239T3 (da) * 2006-11-30 2012-05-29 Res Dev Foundation Forbedrede immunoglobulin-biblioteker
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque
BR112013023040A2 (pt) 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
EP2736522A1 (en) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
US9493515B2 (en) 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA033666B1 (ru) 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ， インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
JP2004521873A (ja) * 2000-11-24 2004-07-22 イシス・イノベイシヨン・リミテツド 混合フィブリル
JP2005532276A (ja) * 2002-03-05 2005-10-27 ラモト アト テル−アヴィヴ ユニバーシティ リミテッド 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法
JP2006520358A (ja) * 2003-03-14 2006-09-07 グラクソ　グループ　リミテッド アルツハイマー病の治療のためのａｓｐ２阻害活性を有するヒドロキシエチルアミン化合物
WO2007095616A2 (en) * 2006-02-15 2007-08-23 Ramot At Tel Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
JP2007532093A (ja) * 2003-05-20 2007-11-15 サントル　ナショナル　ドゥ　ラ　ルシェルシュ　シアンティフィク エングレイルド転写因子の活性を調節するペプチド
WO2008011503A2 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
JP2008527005A (ja) * 2005-01-14 2008-07-24 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア ドルーゼン形成を阻害するため、およびドルーゼン関連障害を診断または治療するための組成物および方法
JP2008528688A (ja) * 2005-02-01 2008-07-31 ラモット アット テル−アビブ ユニバーシティ リミティド アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
JP2004521873A (ja) * 2000-11-24 2004-07-22 イシス・イノベイシヨン・リミテツド 混合フィブリル
JP2005532276A (ja) * 2002-03-05 2005-10-27 ラモト アト テル−アヴィヴ ユニバーシティ リミテッド 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法
JP2006520358A (ja) * 2003-03-14 2006-09-07 グラクソ　グループ　リミテッド アルツハイマー病の治療のためのａｓｐ２阻害活性を有するヒドロキシエチルアミン化合物
JP2007532093A (ja) * 2003-05-20 2007-11-15 サントル　ナショナル　ドゥ　ラ　ルシェルシュ　シアンティフィク エングレイルド転写因子の活性を調節するペプチド
JP2008527005A (ja) * 2005-01-14 2008-07-24 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア ドルーゼン形成を阻害するため、およびドルーゼン関連障害を診断または治療するための組成物および方法
JP2008528688A (ja) * 2005-02-01 2008-07-31 ラモット アット テル−アビブ ユニバーシティ リミティド アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法
WO2007095616A2 (en) * 2006-02-15 2007-08-23 Ramot At Tel Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2008011503A2 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates

Also Published As

Publication number Publication date
AU2009316326A1 (en) 2010-05-27
MX2011005430A (es) 2011-10-28
CO6390112A2 (es) 2012-02-29
ZA201104701B (en) 2012-09-26
HK1162964A1 (en) 2012-09-07
SG171791A1 (en) 2011-07-28
EP2478911A1 (en) 2012-07-25
US20110286970A1 (en) 2011-11-24
NZ592928A (en) 2012-12-21
IL213120A0 (en) 2011-07-31
CN102223887A (zh) 2011-10-19
EP2358377A2 (en) 2011-08-24
KR20110091778A (ko) 2011-08-12
WO2010060073A2 (en) 2010-05-27
WO2010060073A3 (en) 2010-09-02
CA2744339A1 (en) 2010-05-27
BRPI0921557A2 (pt) 2019-09-24
CN102223887B (zh) 2013-11-06
RU2011125971A (ru) 2012-12-27

Similar Documents

Publication Publication Date Title
Cascella et al. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies
Wang et al. The release and trans-synaptic transmission of Tau via exosomes
CN104781278B (zh) 针对tau的抗体
Söllvander et al. Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons
CN102223887B (zh) 使用丝状噬菌体治疗帕金森病的方法
Neniskyte et al. Neuronal death induced by nanomolar amyloid β is mediated by primary phagocytosis of neurons by microglia
SA520411188B1 (ar) جسم مضاد مربوط بالفا - ساينوكلين نشط
CA2659032A1 (en) Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
US8980547B2 (en) Method for treating neurodegenerative tauopathy
JP2009529320A (ja) 脳への送達のための抗体および免疫複合体のバインダーとしてのプロテインａをディスプレイする繊維状バクテリオファージ
US20110182948A1 (en) Method for treating disease characterized by plaque
Teng et al. Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs
Vitale et al. Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models
US20260062480A1 (en) Human blood-brain barrier targeting antibodies
Medecigo et al. Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries
US10451637B2 (en) Synthetic blood vessels and uses thereof
HK1162964B (en) Method for treating parkinson' s disease using filamentous bacteriophage
Bonfante Discovery and characterisation of anti-amyloid beta fibril antibodies from naive phage display VHH libraries
Wolff Investigation of the protective efficacy of α-synuclein-specific antibodies in a novel neuronal cell model for α-synucleinopathies
El Khoury Establishment of a differentiated in vitro model of non-human primate blood-brain barrier and development of a method to quantify endosomal sorting to explore cerebral drug delivery by receptor-mediated transcytosis
Solomon Bacteriophage Therapies Targets Multiple Diseases Caused by Protein Misfolding
Peres Role for lipids in the cellular transmission of α-synuclein
WO2025084396A1 (ja) 抗シナプトタグミン２抗体
WO2025084397A1 (ja) 抗シナプトタグミン２抗体
WO2025084393A1 (ja) 抗シナプトタグミン２抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630